Abstract | BACKGROUND AND PURPOSE: METHODS: RESULTS:
Darbepoetin alfa-treated rats showed improved neuroscores relative to vehicle-treated animals beginning within 1 hour of treatment and persisting throughout the 14-day survival period. Darbepoetin alfa significantly reduced corrected total (cortical + subcortical) infarct volume (56.3+/-20.6 and 110.8+/-6.8 mm3, respectively) and total infarct areas at multiple levels compared with vehicle in the 14-day survival group. Brain swelling was not affected by treatment. CONCLUSIONS:
|
Authors | Ludmila Belayev, Larissa Khoutorova, Weizhao Zhao, Alexey Vigdorchik, Andrey Belayev, Raul Busto, Ella Magal, Myron D Ginsberg |
Journal | Stroke
(Stroke)
Vol. 36
Issue 5
Pg. 1071-6
(May 2005)
ISSN: 1524-4628 [Electronic] United States |
PMID | 15790949
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Neuroprotective Agents
- Recombinant Proteins
- Erythropoietin
- Darbepoetin alfa
|
Topics |
- Animals
- Behavior, Animal
(drug effects)
- Brain Edema
(drug therapy, pathology)
- Brain Ischemia
(diagnosis, drug therapy)
- Darbepoetin alfa
- Erythropoietin
(analogs & derivatives, genetics, therapeutic use)
- Infarction, Middle Cerebral Artery
(pathology)
- Male
- Neuroprotective Agents
(therapeutic use)
- Rats
- Rats, Sprague-Dawley
- Recombinant Proteins
(therapeutic use)
|